Johnson and Johnson: European Commission Approves Expanded Use of HIV-1 Therapy Edurant in Younger Pediatric Patients
October 29, 2024
October 29, 2024
NEW BRUNSWICK, New Jersey, Oct. 29 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
Approval provides a new treatment option for some of the youngest people living with HIV-1 in the European Union
* * *
Beerse, Belgium (October 28, 2024) - Johnson & Johnson today announced that the European Commission (EC) has approved EDURANT (rilpivirine) for the treatment of HIV-1 infection in adults and children weighing at least . . .
* * *
Approval provides a new treatment option for some of the youngest people living with HIV-1 in the European Union
* * *
Beerse, Belgium (October 28, 2024) - Johnson & Johnson today announced that the European Commission (EC) has approved EDURANT (rilpivirine) for the treatment of HIV-1 infection in adults and children weighing at least . . .